Business Description
PMV Pharmaceuticals Inc
NAICS : 541714
SIC : 2833
Description
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 22.03 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -29.3 | |||||
| 3-Year EPS without NRI Growth Rate | -31.6 | |||||
| 3-Year FCF Growth Rate | -28.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.36 | |||||
| 9-Day RSI | 40.09 | |||||
| 14-Day RSI | 40.28 | |||||
| 6-1 Month Momentum % | -33.14 | |||||
| 12-1 Month Momentum % | -53.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 24.76 | |||||
| Quick Ratio | 24.76 | |||||
| Cash Ratio | 24.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -22.44 | |||||
| ROA % | -20.98 | |||||
| ROIC % | -226.44 | |||||
| ROC (Joel Greenblatt) % | -498.14 | |||||
| ROCE % | -21.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.96 | |||||
| Price-to-Tangible-Book | 1.96 | |||||
| EV-to-EBIT | -3.94 | |||||
| EV-to-EBITDA | -3.96 | |||||
| EV-to-FCF | -4.55 | |||||
| Price-to-Net-Current-Asset-Value | 2.1 | |||||
| Price-to-Net-Cash | 2.14 | |||||
| Earnings Yield (Greenblatt) % | -25.32 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PMVP
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -1.52 | ||
| Beta | 0 | ||
| Volatility % | 66.73 | ||
| 14-Day RSI | 40.28 | ||
| 14-Day ATR ($) | 0.906005 | ||
| 20-Day SMA ($) | 12.7145 | ||
| 12-1 Month Momentum % | -53.29 | ||
| 52-Week Range ($) | 8.99 - 30.4 | ||
| Shares Outstanding (Mil) | 45.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PMV Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
PMV Pharmaceuticals Inc Analysis
Share your researchHeadlines
See More
No news.